This site is intended for health professionals only

Cymbalta recommended for approval


The antidepressant drug Cymbalta has been recommended for approval to ease chronic back pain in some patients by a US medical advisory panel.

The Eli Lilly and Co drug has been backed by a US Food and Drug Administration panel of outside advisers after a number of votes. The panel voted in favour of the drug’s wider use but was divided on whether it effectively treated osteoarthritis and lower-back pain.

Its use for back pain was approved by eight votes to five, however it was found there was not enough evidence to support its use to treat osteoarthritis, with the panel voting nine to four against.

Article continues below this sponsored advert
Cogora InRead Image
Explore the latest advances in respiratory care at events delivered by renowned experts from CofE

Panel chairman and head of anaesthesiology at Oregon Health and Science University Jeffrey Kirsch said: “I think it will be a very useful drug for a significant number of patients.”

Cymbalta has already been cleared to treat anxiety, depression, fibromyalgia and diabetes-related pain, but the drugmaker is seeking US approval to widen its market.

Copyright Press Association 2010

Eli Lilly and Co

Be in the know
Subscribe to Hospital Pharmacy Europe newsletter and magazine